Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Anemia Drugs May Offer New Weapon Against Cancer Growth, Finnish Researchers Discover
    29 May 2026

    Anemia Drugs May Offer New Weapon Against Cancer Growth, Finnish Researchers Discover

    Medicines commonly prescribed to treat anemia in patients with chronic kidney disease may have an unexpected role in cancer therapy, according to a new study from Finland. Researchers have found that a class of anemia drugs known as HIF-prolyl hydroxylase inhibitors (HIF-PHIs) can interfere with cancer-related processes, potentially helping patients manage both anemia and tumor progression at the same time.

  • Indoco Remedies Shares Jump Over 4% After EU GMP Certification for Baddi Plant
    29 May 2026
    Indoco Remedies Shares Jump Over 4% After EU GMP Certification for Baddi Plant

    Shares of Indoco Remedies gained 4.12% on Friday after the company announced that its Oral Solid Dosage (OSD) manufacturing facility at Baddi, Himachal Pradesh, has received European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority, Berlin. The regulatory approval is expected to strengthen the company's position in regulated European markets and has been welcomed positively by investors.

  • Regeneron Chooses Hyderabad for Its First Global Capability Centre Outside the US
    29 May 2026
    Regeneron Chooses Hyderabad for Its First Global Capability Centre Outside the US

    Global biotechnology company Regeneron Pharmaceuticals has announced plans to establish its first Global Capability Centre (GCC) outside the United States in Hyderabad, further strengthening Telangana's position as a leading destination for global life sciences and technology investments.

  • CDSCO Approves Wockhardt’s Breakthrough Antibiotic ZAYNICH® for Complicated Urinary Tract Infections
    28 May 2026
    CDSCO Approves Wockhardt’s Breakthrough Antibiotic ZAYNICH® for Complicated Urinary Tract Infections

    Wockhardt has received marketing authorization from India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), for its breakthrough antibiotic ZAYNICH® (Zidebactam/Cefepime). The approval marks a significant milestone for India’s fight against antimicrobial resistance, especially in difficult-to-treat Gram-negative bacterial infections.

  • Sun Pharma to Present Long-Term UNLOXCYT Data at ASCO 2026
    28 May 2026
    Sun Pharma to Present Long-Term UNLOXCYT Data at ASCO 2026

    Mumbai-based Sun Pharmaceutical Industries Limited has announced that it will present updated long-term clinical data for UNLOXCYT™ (cosibelimab-ipdl) at the upcoming ASCO Annual Meeting in Chicago. The presentation will focus on patients suffering from locally advanced cutaneous squamous cell carcinoma (laCSCC), a serious form of skin cancer.

  • Scientists Discover How Lung Cancer Cells Change Identity to Escape Treatment
    27 May 2026
    Scientists Discover How Lung Cancer Cells Change Identity to Escape Treatment
    Researchers at University of Southampton have uncovered a key mechanism that allows lung cancer cells to become more aggressive and resistant to treatment by switching back to an earlier developmental state.
  • Scientists Discover New Way to Make Immunotherapy More Effective in Breast Cancer
    27 May 2026
    Scientists Discover New Way to Make Immunotherapy More Effective in Breast Cancer
    Researchers from Medical University of Vienna have identified a major mechanism that allows breast cancer tumours to escape the body’s immune system, opening the door for more effective immunotherapy treatments in the future.
  • AstraZeneca’s Breast Cancer Drug Camizestrant faces US FDA Delay as Agency Seeks More Clinical Data
    27 May 2026
    AstraZeneca’s Breast Cancer Drug Camizestrant faces US FDA Delay as Agency Seeks More Clinical Data
    Pharma major AstraZeneca has received an extension in the US FDA review timeline for its investigational breast cancer therapy camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) being evaluated for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.
  • AstraZeneca-Daiichi’s Datroway Wins US Approval for Aggressive Breast Cancer
    27 May 2026
    AstraZeneca-Daiichi’s Datroway Wins US Approval for Aggressive Breast Cancer

    AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved DATROWAY (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval makes DATROWAY the first TROP2-directed antibody-drug conjugate (ADC) approved in the United States for first-line treatment in this patient population.

  • NTU Singapore Develops Seed-Sized “5-in-1” Surgical Robot for Future Medical Procedures
    26 May 2026
    NTU Singapore Develops Seed-Sized “5-in-1” Surgical Robot for Future Medical Procedures

    Scientists at Nanyang Technological University, Singapore have developed an ultra-small surgical robot capable of performing five different medical functions wirelessly inside the body, marking a major step toward more precise and minimally invasive treatments.

Subscribe to Pharma News